Today PAREXEL Consulting (Boston, MA) released its second annual study on the state of the FDA drug review process. Findings are captured in the white paper The Innovation Imperative in the Safety First Era, which answers questions such as:
“The implications of FDAAA and CDER’s implementation of the law have been widely discussed, and there is considerable conjecture in the biopharmaceutical industry regarding how FDA review timelines and the approval process are being impacted by new requirements, such as REMS," said Mark Mathieu, Director of Strategic Research at PAREXEL Consulting and the study’s lead author. "What our research provides is a real-world, metrics-based assessment to help inform expectations of new drug review outcomes in the Safety First Era."
That assessment also includes discussions on real-world implications of overdue NDA reviews on first-cycle approval rates and why priority-rated drugs continue to have advantages in the drug review process, despite their decline.
To find out more, the white paper is available for down load here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.